NEW ORLEANS — The addition of daratumumab to lenalidomide and dexamethasone continued to benefit transplant-ineligible patients with newly diagnosed multiple myeloma, according to updated results of the randomized phase 3 MAIA study.
The daratumumab (Darzalex, Janssen) regimen appeared associated with longer PFS and OS, as well as a nearly threefold increase in minimal residual disease negativity rate, findings presented at ASH Annual Meeting and Exposition showed.
Researcher Shaji K. Kumar, MD — consultant in the division of hematology and professor of medicine at Mayo Clinic in
